WANA (Nov 18) – An Iranian research team, led by Banafsheh Heydari and Atefeh Shahbazi, has introduced a series of biologic products derived from human embryonic and placental tissues to treat chronic wounds—particularly in diabetic patients at high risk of limb amputation.

 

According to the research team, these products have demonstrated high clinical effectiveness, significantly accelerating wound closure and promoting natural healing processes.

 

Biologic Products Target Natural Tissue Repair

The newly developed technologies focus on enhancing the body’s natural tissue-repair pathways, helping wounds heal within standard recovery periods while minimizing scar formation.

 

A key component of the product suite is a purified acid compound designed to treat the most resistant chronic wounds—cases that often fail to heal due to underlying conditions, poor nutrition, or infections.

 

Innovative Wound Dressings From Amniotic Tissue

Among the innovations is a wound dressing derived from the embryonic amniotic membrane, which forms a protective cellular layer over the injury and facilitates tissue regeneration.

 

The product line also includes purified hyaluronic acid extracts sourced from human placental tissue, offered in both liquid and powder forms.

 

In the most advanced product, differentiated stem cells are integrated into the biological base to increase treatment efficacy in severe cases.

 

These biologic technologies were developed to achieve complete tissue repair while avoiding long-term complications, offering a new therapeutic option for patients suffering from chronic wounds.

Nine Cold Plasma Wound Clinics Opened in Iran

Nine Cold Plasma Wound Clinics Opened in Iran. Social media/ WANA News Agency